GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » EV-to-FCF

Calithera Biosciences (STU:2CB0) EV-to-FCF : 0.21 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Calithera Biosciences's Enterprise Value is €-8.62 Mil. Calithera Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was €-41.12 Mil. Therefore, Calithera Biosciences's EV-to-FCF for today is 0.21.

The historical rank and industry rank for Calithera Biosciences's EV-to-FCF or its related term are showing as below:

STU:2CB0's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 6.365
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Calithera Biosciences's stock price is €0.045. Calithera Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was €-6.803. Therefore, Calithera Biosciences's PE Ratio for today is At Loss.


Calithera Biosciences EV-to-FCF Historical Data

The historical data trend for Calithera Biosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences EV-to-FCF Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 -2.71 -2.83 0.08 -0.33

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.17 0.08 -0.08 -0.33

Competitive Comparison of Calithera Biosciences's EV-to-FCF

For the Biotechnology subindustry, Calithera Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's EV-to-FCF falls into.



Calithera Biosciences EV-to-FCF Calculation

Calithera Biosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-8.615/-41.123
=0.21

Calithera Biosciences's current Enterprise Value is €-8.62 Mil.
Calithera Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences  (STU:2CB0) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Calithera Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.045/-6.803
=At Loss

Calithera Biosciences's share price for today is €0.045.
Calithera Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.803.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Calithera Biosciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (STU:2CB0) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines